Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

Medications, for article on Medicare drug price negotiation

The U.S. negotiates Medicare drug price cuts that will save billions for U.S. citizens

By / / Good News For Humankind

Medicare drug price negotiation just delivered its first results, and the projected savings land at roughly $6 billion a year once new prices take effect in January 2026. After nearly six decades of being legally barred from bargaining with drugmakers, Medicare negotiated discounts on 10 widely used medications, including the blood thinner Eliquis and the diabetes drug Januvia. Some prices dropped by as much as 79%, with the deepest cuts going to drugs that faced the least competition. Around 9 million enrollees use these medications, and a new $2,000 annual cap on out-of-pocket drug costs adds further relief. Beyond the dollars, this shifts what’s politically possible — moving the U.S. closer to how most wealthy democracies have long approached medicine pricing.

Good news for public health, for article on CAB-LA HIV prevention, for article on lenacapavir HIV prevention, for article on HIV infections in young men

New twice-yearly shot to prevent HIV achieves 100% success rate in late-stage trial

By / / Good News For Humankind

Lenacapavir, a twice-yearly HIV prevention shot, protected every single one of 2,134 women who received it in a late-stage trial across South Africa and Uganda — a 100% efficacy result so striking that monitors ended the blinded phase early. The breakthrough matters because daily prevention pills, while powerful in theory, often falter in real life: stigma, forgotten doses, and disrupted routines all chip away at protection. Two clinic visits a year, by contrast, means a full year of coverage. The remaining hurdle is access, with advocates pressing manufacturer Gilead to license generic versions for the regions hardest hit. If that happens, a tool this effective could reshape the global push to end the HIV epidemic by 2030.

Silhouette of cannabis leaf, for article on Maryland marijuana pardons

Maryland Gov. Wes Moore set to issue 175,000 pardons for marijuana convictions

By / / Good News For Humankind

Maryland’s marijuana pardons just cleared more than 175,000 convictions in a single executive order — the largest state-level pardon any governor has ever signed. Governor Wes Moore framed it as unfinished business from legalization itself, noting that people arrested for cannabis decades ago still carry those records into job interviews, housing applications, and college admissions today. The order falls hardest in favor of Black Marylanders, who were arrested for cannabis at three times the rate of white residents before the state legalized recreational use in 2023. Moore was honest about the limits: a pardon can’t return lost years. But paired with the federal push to reschedule marijuana, it signals a country slowly reckoning with who paid the price of the war on drugs.

X-ray image of the intestine, for article on dostarlimab bowel cancer trial

New bowel cancer drug is found to be 100% effective

By / / Good News For Humankind

Immunotherapy just delivered something almost unheard of in cancer research: every single one of 42 patients in a rectal cancer trial showed no detectable tumour after treatment with the drug dostarlimab. Even more encouraging, the first 24 patients have now been tracked for an average of 26 months, and their cancers haven’t come back. For people with this specific subtype, it could mean skipping the chemotherapy, radiation, and surgery that often leave lasting damage. Larger studies are now underway to confirm the findings, but the signal is remarkable. It’s a glimpse of where cancer care may be heading worldwide — treatments that work with the body’s own immune system, and let patients keep their lives intact.

Contraceptives, for article on free contraception program

Free contraception initiative helps Finland reduce teenage abortions by 66%

By / / Good News For Humankind

Free contraception cut Finland’s teen abortion rate by 66% over roughly two decades, one of the steepest drops ever recorded in a high-income country. The shift came when municipalities began quietly weaving no-cost birth control into the same youth clinics where teenagers already get vaccines and check-ups, no awkward conversations or out-of-pocket costs required. Researchers say the lesson is refreshingly simple: young people aren’t avoiding contraception because they don’t understand it, but because of cost, stigma, or logistics — and Finland removed all three. As governments worldwide search for ways to support young people’s health and futures, this offers a quietly powerful blueprint: trust teenagers, meet them where they are, and the rest tends to follow.

Holding breast cancer ribbon, for article on breast cancer recurrence blood test

New blood test can predict breast cancer return

By / / Good News For Humankind

A new blood test for breast cancer recurrence spotted returning disease an average of 15 months before symptoms or scans — and in one case, a full 41 months ahead of diagnosis. In a UK trial of 78 patients, the test correctly flagged every woman who later relapsed, scanning for 1,800 cancer-related mutations in tiny fragments of tumour DNA left circulating after treatment. Lead researcher Dr. Isaac Garcia-Murillas explained that dormant cells too few to show up on scans can trigger relapse years later — exactly the blind spot this test targets. If larger studies confirm the results, a simple blood draw could give oncologists precious extra time to act, reshaping how recurrence is caught worldwide.

A researcher handling a vaccine vial in a clinical lab for an article about cancer vaccine trials, for article on cancer chemotherapy, for article on personalized cancer vaccine

NHS launches world-first cancer vaccine matchmaking program in England

By / / Good News For Humankind

Cancer vaccine trials are now being fast-tracked through a landmark NHS program in England that matches patients with personalized mRNA vaccines built around their individual tumors. The Cancer Vaccine Launch Pad, operating across 30 hospitals, uses the same mRNA technology behind COVID-19 vaccines to design custom treatments targeting each patient’s unique cancer mutations. The program aims to eliminate remaining cancer cells after surgery before they can return. Early immune response data is encouraging, and a 2024 trial showed a 44% reduction in melanoma recurrence when similar vaccines were combined with immunotherapy.

Aral Sea time lapse 1989 2014, for article on Aral Sea afforestation

Uzbekistan plants millions of acres of forest where the Aral Sea once lay

By / / Good News For Humankind

Aral Sea afforestation has covered 1.7 million hectares of dried lakebed with saxaul trees and other desert-tolerant plants over the past five years, transforming what was once the world’s fourth-largest lake into a slowly recovering landscape. The work is led on the ground by Karakalpak communities, where women gather seeds each autumn and men join planting crews through the winter. A single mature saxaul shrub can hold back several tons of moving sand, shielding nearby towns from the toxic dust storms that have driven respiratory illness for decades. It’s an imperfect, weather-dependent effort — but a hopeful model for how nature-based restoration can heal landscapes that seemed beyond saving.

A neuron or nerve cell is an electrically excitable cell, for article on ALS synapse-regenerating pill

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

By / / Good News For Humankind

A once-daily ALS pill designed to rebuild neural connections — not just slow their loss — has cleared FDA approval to begin Phase 2 trials, with patients across the U.S. starting doses in April 2024. SPG302 works on synapses, the tiny junctions where neurons talk to each other, which start vanishing before motor neurons themselves die. Every ALS drug currently on the market aims to slow decline; this one is being tested for whether it can actually help recover lost function. For the roughly 30,000 Americans living with ALS, that’s a genuinely different question to be asking. If it works, it could reshape how researchers approach neurodegenerative disease far beyond ALS.

Good news for public health, for article on CAB-LA HIV prevention, for article on lenacapavir HIV prevention, for article on HIV infections in young men

HIV transmissions in the U.S. dropped 12% between 2018 and 2002

By / / Good News For Humankind

HIV infections among young men in the U.S. dropped 30% between 2018 and 2022, the steepest decline of any age group in the latest CDC surveillance data. Researchers credit expanded testing, faster connection to treatment, and the growing reach of PrEP — a daily pill that cuts transmission risk by up to 99% when taken consistently. The South, long carrying the heaviest HIV burden in the country, saw the largest regional drop, and Black men experienced an 18% decline. Gaps remain, especially for transgender women and Latino gay men, but the news from this generation is genuinely hopeful: when prevention tools reach people early, they work. It’s a glimpse of what ending the epidemic could actually look like.